Comparison of the Subcutaneous Absorption of Insulin Glargine (Lantus®) and NPH Insulin in Patients with Type 2 Diabetes

Abstract

The aim of this study was to compare the subcutaneous absorption characteristics of insulin glargine with NPH insulin in patients with Type 2 diabetes. In this single-dose, double-blind, randomized, two-way crossover study, 14 patients with Type 2 diabetes (aged 40 - 70 years) previously untreated with insulin were randomized to receive in a fasting state either a single subcutaneous injection of 0.3 U/kg ¹²⁵I-insulin glargine or 0.3 U/kg ¹²⁵I-NPH insulin. The disappearance of radioactivity was monitored for forty-eight hours. The median time for 25 %, 50 % and 75 % of the radioactivity to disappear from the injection site was significantly longer for insulin glargine compared with NPH insulin (T_{75 %} 15.0 and 6.5 h, p = 0.009; T_{50 %} 26.3 and 13.4 h, p = 0.009; T_{25 %} 42.4 and 26.6 h, p = 0.019, respectively). The mean residual radioactivity remaining at 24, 36 and 48 h after injection remained significantly higher than NPH insulin (54.4 and 27.9 %, p = 0.0001; 35.0 and 17.0 %, p = 0.003; 19.2 and 9.2 %, p = 0.01, respectively). Mean plasma glucose levels reached a minimum after 14.6 and 9 h in response to insulin glargine and NPH insulin, respectively. The subcutaneous absorption of insulin glargine in fasting Type 2 diabetes patients was significantly (2 - 3 times) slower compared with NPH insulin in patients with Type 2 diabetes. The slower absorption of insulin glargine correlated with the fall in plasma glucose levels over a 24 h period compared with the faster insulin absorption and more rapid decrease in plasma glucose levels observed in response to NPH insulin. Both insulin glargine and NPH insulin were well tolerated.

Absorption - Insulin - Type 2 diabetes

References

• 1 UKPDS . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet. 1998;  352 837-853
• 2 Turner R, Cull C, Frighi V, Holman R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.  JAMA. 1999;  281 2005-2012
• 3 Yki-Jarvinen H, Ryysey L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus.  Ann Intern Med. 1999;  130 389-396
• 4 Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.  Diabetes Care. 2000;  23 644-649
• 5 Ciofetta M, Lalli C, Del Sindaco P D, Torlone E, Pampanelli S, Mauro L, Chiara D L, Brunetti P, Bolli G B. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime.  Diabetes Care. 1999;  22 795-800
• 6 Owens D R. Human insulin: clinical pharmacological studies in normal man. In: Owens DR (ed) Lancaster; MTP Press 1986
• 7 Bolli G, DiMarchi R, Park G, Pramming S, Koivisto V A. Insulin analogues and their potential in the management of diabetes mellitus.  Diabetologia. 1999;  42 1151-1167
• 8 Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics.  Diabetes Care. 1984;  7 188-199
• 9 Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli G B. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.  Diabetes. 2000;  49 2142-2148
• 10 Rosskamp R H, Park G. Long-acting insulin analogs.  Diabetes Care. 1999;  22 B109-B113
• 11 Hildebrandt P. Subcutaneous absorption of insulin in insulin-dependent diabetic patients. Influence of species, physio-chemical properties of insulin and physiological factors.  Dan Med Bull. 1991;  38 337-346
• 12 Heinemann L, Linkeschowa R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.  Diabetes Care. 2000;  23 (5) 644-649
• 13 Owens D, Coates P, Luzio S, Tinbergen J P, Kurzhals R. Pharmacokinetics of [125]I- labelled insulin glargine (HOE 901) in healthy men.  Diabetes Care. 2000;  23 813-819
• 14 Gliemann J, Sonne O, Linde S, Hansen B. Biological potency and binding affinity of monoiodoinsulin with iodine in tyrosine A14 or tyrosine A19.  Biochem Biophys Res Commun. 1979;  87 1183-1190
• 15 Ferraiolo B L. Protein pharmacokinetics and metabolism.  Pharmaceutical Biotechnology, Vol. 1. In: Ferraiolo BL, Mohler MA, Glof CA (eds) New York; Plenum Publication Corporation 1992
• 16 Cryer P. Hypoglycaemia is the limiting factor in the management of diabetes.  Diabetes Metab Res Rev. 1999;  15 42-46
• 17 Matthews D, Pfeiffer C. A new long-acting insulin (HOE901) demonstrates less nocturnal hypoglycaemia when compared with protamine insulin in a clinical trial.  Diabetologia. 1998;  41 A245 (Abstract 948)
• 18 Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in Type 2 diabetes.  Diabetes Care. 2000;  23 1130-1136